Birch Allergy – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034

 Birch Allergy Market Outlook

Thelansis’s “Birch Allergy Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Birch Allergy treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Birch Allergy Overview

Birch belongs to the order Fagales and the family Betulaceae, which are widely distributed across the United States. Numerous species of birch trees can be found throughout the country, contributing to allergies. The European white birch (Betula pendula) and River birch (Betula nigra) are the two most prevalent varieties. Birch pollen is a significant allergen inhaled from the air, particularly in the northern temperate region. This pollen often leads to allergic rhinitis, asthma, and allergies to certain foods associated with pollen exposure. The prevalence of sensitivity to birch pollen is approximately 8-16% in the general population and ranges from 7-57% among patients attending various allergy clinics. The International Allergen Nomenclature Sub-committee has recognized seven allergens associated with birch pollen, with Bet v 1 being the primary allergen. To enhance diagnostic accuracy, component-resolved testing can differentiate broad cross-reactivity and prevent false-positive diagnoses of pollen allergies attributed to pan-allergens like Bet v 2, 4, or Bet v 7, from genuine birch allergies involving the main allergen Bet v 1-specific IgE. Oral Allergy Syndrome (OAS) symptoms may manifest as:

• Tingling or itching in the mouth
• Hives around the mouth
• Irritation or discomfort in the throat
• Swelling of the lips, mouth, tongue, or throat

Individuals displaying allergic reactions to birch pollen exhibit notably higher levels of serum anti-Bet v 1 IgE compared to individuals with birch sensitivity who remain asymptomatic. Elevated IgE levels related to Bet v 1 are also predictive of oral allergy syndrome following consuming fruits from the Rosaceae family, nuts, or vegetables from the Apiaceae family, which contain homologous allergens cross-reactive with birch allergens.

 

Geography coverage:

G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)

Insights driven by robust research, including:

• In-depth interviews with leading KOLs and payers
• Physician surveys
• RWE analysis for claims and EHR datasets
• Secondary research (e.g., peer-reviewed journal articles, third-party research databases)

Deliverables format and updates*:

• Detailed Report (PDF)
• Market Forecast Model (MS Excel-based automated dashboard)
• Epidemiology (MS Excel; interactive tool)
• Executive Insights (PowerPoint presentation)
• Others: regular updates, customizations, consultant support

*As per Thelansis’s policy, we ensure that we include all the recent updates before releasing the report content and market model.

Salient features of Market Forecast model:

• 10-year market forecast (2024–2034)
• Bottom-up patient-based market forecasts validated through the top-down sales methodology
• Covers clinically and commercially-relevant patient populations/ line of therapies
• Annualized drug-level sales and patient share projections
• Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
• Detailed methodology/sources & assumptions
• Graphical and tabular outputs
• Users can customize the model based on requirements

Key business questions answered:

• How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)?
• How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
• What is the 10-year market outlook for sales and patient share?
• Which events will have the greatest impact on the market’s trajectory?
• What insights do interviewed experts provide on current and emerging treatments?
• Which pipeline products show the most promise, and what is their potential for launch and future positioning?
• What are the key unmet needs and KOL expectations for target profiles?
• What key regulatory and payer requirements must be met to secure drug approval and favorable market access?
• and more…

Read more: Birch Allergy – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034